Skip to content
OpenCapital
Get started

Kiniksa Pharmaceuticals International, plc KNSA EPS (Basic)

EPS (Basic) at other companies

Ligand Pharmaceuticals logo
Ligand PharmaceuticalsLGND
-$0.67+69.7%
Aurinia Pharmaceuticals logo
Aurinia PharmaceuticalsAUPH
$0.26+52.9%
Agios Pharmaceuticals logo
Agios PharmaceuticalsAGIO
-$1.69-9.0%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
-$0.84+4.5%
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
-$1.84-17.2%
LQD
Liquidia CorporationLQDA
$0.60+233%

Other financials

Income statement

See full
Revenue$214.3M+55.5%
Gross profit$193.5M+61.3%
Operating income$29.3M+121%
Net income$22.6M+165%
EPS (diluted)$0.27+145%

Balance sheet

See full
Cash & equivalents$190.0M+20.9%
Total debt$9.0M-9.0%
Total equity$605.7M+32.4%
Total assets$825.3M+37.7%

Cash flow

See full
Operating cash flow$50.2M+125%
CapEx$161.0K+62.6%
Free cash flow$50.0M+125%

Valuation

See full
Market cap$4.58B+128%

Profitability

See full
Gross margin89.3%+3.5pp
Operating margin12.4%+10.2pp
Net margin9.7%+7.6pp
FCF margin21.8%+12.2pp

Returns & leverage

See full
Return on equity13.7%+11.3pp
Debt / equity0×0.0×
Current ratio3.8×+0.1×

Where this comes from

Reported directly by Kiniksa Pharmaceuticals International, plc in its filing.

Tagged under the XBRL concept us-gaap:EarningsPerShareBasic.

The official record: Kiniksa Pharmaceuticals International, plc’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →

Ask your AI about Kiniksa Pharmaceuticals International, plc's eps (basic).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Kiniksa Pharmaceuticals International, plc's EPS (basic)?
Kiniksa Pharmaceuticals International, plc (KNSA) reported EPS (basic) of $0.30 in Q1 2026.
How has Kiniksa Pharmaceuticals International, plc's EPS (basic) changed year-over-year?
Kiniksa Pharmaceuticals International, plc's EPS (basic) increased by 150.0% year-over-year, from $0.12 to $0.30.
What is the long-term trend for Kiniksa Pharmaceuticals International, plc's EPS (basic)?
Over 4 years (2021 to 2025), Kiniksa Pharmaceuticals International, plc's EPS (basic) has grown at a -23.1% compound annual growth rate (CAGR), from -$2.29 to $0.80.
What does EPS (basic) mean?
Net income available to common shareholders divided by the weighted-average number of common shares outstanding during the period. Does not account for dilutive securities.